Table 2.
Baseline characteristics of study populationa
| Overall (n = 188) | |
|---|---|
| Age (yr) | 65 (59–71) |
| PSA (ng/ml) | 6.0 (4.9–8.3) |
| Prostate volume (ml) | 46.0 (36.5–61.0) |
| PSA density (ng/ml/ml) | 0.14 (0.10–0.19) |
| cT, n (%) | |
| T1a | 18 (9.6) |
| T1b | 5 (2.7) |
| T1c | 162 (86.2) |
| T2a | 3 (1.6) |
| GG, n (%) | |
| 1 | 171 (91.0) |
| 2 | 17 (9.0) |
| PI-RADS score, n (%) | |
| 1–2 | 76 (40.8) |
| 3 | 49 (26.1) |
| 4 | 57 (30.3) |
| 5 | 6 (3.2) |
cT = clinical T stage; GG = Gleason grade group; PI-RADS = Prostate Imaging Reporting and Data System; PSA = prostate-specific antigen.
a
Data are shown as medians and interquartile range for continuous variables, and as counts and percentages for categorical variables.